Generated by AI
CytoSorbents Corporation is a medical device company focused on blood purification technologies for critical care and cardiac surgery. CytoSorbents Corporation develops and commercializes products that use hemoadsorption to remove harmful substances from blood, including inflammatory mediators, bilirubin, myoglobin, and certain antithrombotic drugs. Its portfolio includes CytoSorb for intensive care and surgical applications, DrugSorb-ATR for removing blood thinners, and additional blood purification and filtration technologies for specialized clinical and veterinary uses. The company serves hospitals and clinicians in the United States, Europe, and other international markets, with an emphasis on treating life-threatening conditions such as sepsis, severe inflammation, and complications associated with surgery and organ failure. Headquartered in Princeton, New Jersey, CytoSorbents Corporation plays a niche role in the medical technology market through its proprietary polymer-based adsorption platform.
Website305 College Road East
Princeton, NJ, 08540
United States
The latest articles about CTSO.
CytoSorbents Corp (CTSO) hit operating cash flow breakeven and lifted product gross margin to 75% in Q3 2026, while outlining an early 2027 de novo submission for DrugSorb ATR.
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the third quarter ended September 30, 2026, recent business highlights, and provides a regulatory update.
Summary of Mar 25's posts. Generated by AI.
No summary yet.
Summary of Jan 3's posts. Generated by AI.
Summary of Dec 28's posts. Generated by AI.
Investors talking about CTSO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.